Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2007-10-23
2007-10-23
Steadman, David J. (Department: 1656)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C436S004000, C435S183000
Reexamination Certificate
active
10741208
ABSTRACT:
The present invention discloses purified polypeptides that comprise an active human ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human ADAM33 catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human ADAM33. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human ADAM33 in structure based drug design to identify compounds that can modulate the enzymatic activity of human ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the human ADAMS33 catalytic domain.
REFERENCES:
patent: 5830742 (1998-11-01), Black et al.
patent: 6013466 (2000-01-01), Black et al.
patent: 6420154 (2002-07-01), Sheppard et al.
patent: 2004/0002470 (2004-01-01), Keith et al.
patent: 2004/0023215 (2004-02-01), Keith et al.
patent: 2004/0077011 (2004-04-01), Keith et al.
patent: 2004/0151715 (2004-08-01), Orth et al.
patent: 2004/0152869 (2004-08-01), Zhang et al.
patent: WO 03/031594 (2003-04-01), None
Buts et al., Acta Crystallogr.-D., vol. 61, pp. 1149-1159, 2005.
Creighton, T., “Encyclopedia of Molecular Biology”, John Wiley and Sons, Inc. New York, 1999, pp. 586 and 2725.
Skarzynski et al., Acta Crystallogr. D., vol. 62, pp. 102-107, 2006.
Kierzek et al., Biophys. Chem., vol. 91, pp. 1-20, 2001.
Wiencek, Annu. Rev. Biomed. Eng., vol. 1, pp. 505-534, 1999.
Ke & Doudna, Methods, vol. 34, pp. 408-414, 2004.
Derewenda et al., Acta Crystallogr. D., vol. 62, pp. 116-124, 2006.
Lopez-Jaramillo et al., Acta Crystallogr. F., vol. 61, pp. 435-438, 2005.
Cudney R. Protein Crystallization and Dumb Luck. The Rigaku Journal. 1999. vol. 16, No. 1, pp. 1-7.
Kundrot, C.E. Which Strategy for a Protein Crystallization Project? Cellular Molecular Life Science. 2004. vol. 61, pp. 525-536.
[ccp4bb]: Summary of Protein Crystallization with His Tags (Dec. 21, 2001). www.ysbl.york.ac.uk/ccp4bb/2001/msg01286.html.
Publications of Bernhard Rupp and PDB deposits: www.ruppweb.org/cvs/Rupp/Publist.htm 2006.
Drenth, “Principles of Protein X-Ray Crystallography”, 2nd Edition, 1999 Springer-Verlag New York Inc., Chapter 1, p. 1-21.
McPherson, Current Approaches to Marcomolecular Crystallization. European Journal of Biochemistry. 1990. vol. 189, pp. 1-23.
Armour, Augustin, et al., “The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs,” FEBS Letters 524:154-8 (2002).
Black, Roy A., et al., “A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells,”Nature385:729-33 (1997).
Bottomley, Kevin M., et al., “Matrix metalloproteinases and the potential therapeutic role for matrix metalloproteinase inhibitors in Chronic Obstructive Pulmonary Disease (COPD),”Annual Reports in Medicinal Chemistry37:209-16 (2002).
Coombs, Gary S., et al., “Substrate specificity of prostate-specific antigen (PSA),”Chemistry&Biology5:475-488 (1998).
Drazen, Jeffrey M., et al., “Inherit the wheeze,”Nature418:383-4 (2002).
Fernandez-Catalan, Carlos, et al., “Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor,”The EMBO Journal17:5238-48 (1998).
Gearing, A.J.H., et al., “Processing of tumor necrosis factor-α precursor by metalloproteinases,”Nature370:555-7 (1994).
Gomis-Rüth, Franz-Xaver, et al., “Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1,”Nature389:77-81 (1997).
Gunn, Teresa M., et al., “Identification and preliminary characterization of mouseAdam33,” BMC Genetics 3:1-8 (2002).
Holgate, ST, et al., “ADAM 33: just another asthma gene or a breakthrough in understanding the origins of bronchial hyperresponsiveness?”Thorax58:466-9 (2003).
Houghten, Richard A., et al., “Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery,”Nature354:84-6 (1991).
Lee, Meng-Huee, et al., “Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: A new frontier in TIMP engineering,”Protein Science11:2493-2503 (2002).
Lind, Denise L., et al., “ADAM33is not associated with asthma in Puerto Rican or Mexican Populations,”American Journal of Respiratory and Critical Care Medicine168:1312-16 (2003).
Maskos, Klaus, et al., “Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme,”Proc. Natl. Acad. Sci.95:3408-12 (1998).
Matthews, David J., et al., “Substrate phage: selection of protease substrates by monovalent phage display,”Science260:1113-7 (1993).
Matthews, David J., et al., “A survey of furin substrate specificity using substrate phage display,”Protein Science3:1197-1205 (1994).
McGeehan, Gerard M., et al., “Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor,”Nature370:558-61 (1994).
Milla, Marcos E., et al., “Specific sequence elements are required for the expression of functional tumor necrosis factor-α-converting enzyme (TACE),” The Journal of Biological Chemistry 274:30563-70 (1999).
Mohan, Mohita J., et al., “The tumor necrosis factor-α converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity,”Biochemmistry41:9462-69 (2002).
Mohler, Kendall M., et al., “Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing,”Nature370:218-220 (1994).
Morgunova, Ekaterina, et al., “Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed,”Science284:1667-70 (1999).
Morris, David G., et al., “Loss of integrin ανβ6-mediated TGF-β activation causes Mmp12-dependent emphysema,”Nature422:169-73 (2003).
Nagase, Hideaki, “Activation Mechanisms of Matrix Metalloproteinases,”Biol. Chem.378:151-160 (1997).
Nagase, Hideaki, et al., “Matrix metalloproteinases,”The Journal of Biological Chemistry274:21491-4 (1999).
Orth, Peter, et al. “Crystal structure of the catalytic domain of human ADAM33,”J. Mol. Biol.335:129-37 (2004).
Polgár, László, “Metalloproteases,” Mechanisms of Protease Action, CRC Press, Inc., Boca Ration, Florida pp. 183-218 (1989).
Postma, D.S., et al., “ADAM33gene: confirming a gene without linkage,”Clin Exp. Allergy34:1-3 (2004).
Roberts, Anita B., “Smoke signals for lung disease,”Nature422:130-1 (2003).
Shapiro, Steven D., et al., “ADAM-33Surfaces as an Asthma Gene,”N Engl J Med347:936-8 (2002).
Smutzer, Gregory, “Molecular Demolition,”The Scientist16:34 (2002).
Turk, Benjamin E., et al., “Determination of protease cleavage site motifs using mixture-based oriented peptide libraries,”Nature Biotechnology19:661-7 (2001).
Van Eerdewegh, Paul, et al., “Association of theADAM33gene with asthma and bronchial hyperresponsiveness,”Nature418:426-30 (2002).
Werner, M., et al., “Asthma is associated with single-nucleotide polymorphisms inADAM33,” Clin Exp Allergy34:26-31 (2004).
Yoshinaka, Tsuyoshi, et al., “Identification and characterization of novel mouse and human ADAM33s with potential metalloprotease activity,”Gene282:227-36 (2002).
Prosise et al., Protease domain of human ADAM33 produced by Drosophila S2 cells. Protein Expr Purif. Dec. 2004;38(2):292-301.
Orth et al., Crystal structure of the catalytic domain of human ADAM33. J Mol Biol. Jan 2
Madison Vincent S.
Orth Peter
Reichert Paul
Wang Wenyan
Zou Jun
Noakes Suzanne M.
Schering Corporation
Steadman David J.
LandOfFree
Crystalline form of an n231 mutant catalytic domain of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline form of an n231 mutant catalytic domain of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline form of an n231 mutant catalytic domain of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3822907